文献速递儿科与产科急症

胎盘生长因子检测用于评估疑似子痫前期孕妇:一项多中心、实用性、阶梯楔形整群随机对照试验

Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
PubMed 文献 · Lancet · 2019-04-01
一句话结论在疑似子痫前期孕妇中,公开胎盘生长因子(PlGF)检测结果并联合临床管理算法,可缩短确诊时间并降低母体严重不良结局,但围产儿结局无差异。

该多中心、实用性、阶梯楔形整群随机对照试验纳入英国11个产科单位、孕20周0天至36周6天、疑似子痫前期的单胎活产孕妇1023例,比较公开PlGF检测结果联合临床管理算法(干预组576例)与常规护理加 conceal 检测(对照组447例)。干预组子痫前期确诊中位时间4.1天 vs 1.9天(时间比0.36,95%CI 0.15-0.87;p=0.027),母体严重不良结局5% vs 4%(校正OR 0.32,95%CI 0.11-0.96;p=0.043),围产儿不良结局15% vs 14%(OR 1.45,95%CI 0.73-2.90)及分娩孕周36.6周 vs 36.8周(均差-0.52,95%CI -0.63至0.73)无差异。作者认为在疑似子痫前期孕妇中采用PlGF检测得到本研究结果支持。

要点

  • 疑似子痫前期孕妇公开PlGF结果联合管理算法,确诊中位时间由4.1天缩短至1.9天(时间比0.36,95%CI 0.15-0.87;p=0.027)。
  • 干预组母体严重不良结局5% vs 4%(校正OR 0.32,95%CI 0.11-0.96;p=0.043),作者认为与算法推荐的目标性加强监测一致。
  • 围产儿不良结局15% vs 14%(OR 1.45,95%CI 0.73-2.90)及分娩孕周36.6周 vs 36.8周(均差-0.52,95%CI -0.63至0.73)无差异证据。
  • 研究为英国11个产科单位的多中心阶梯楔形整群随机试验,孕20周0天至36周6天、单胎活产、疑似子痫前期孕妇。
  • 作者认为疑似子痫前期孕妇采用PlGF检测得到本研究结果支持。

适用人群与场景

  • 年龄18岁及以上、孕20周0天至36周6天、单胎活产、疑似子痫前期的孕妇,由临床研究团队邀请参与。
  • 疑似子痫前期定义为新发或原有高血压加重、试纸蛋白尿、上腹痛或右上腹疼痛、头痛伴视觉障碍、胎儿生长受限,或提示疾病的异常母体血液检查(如血小板减少或肝肾功能异常)。
  • 研究在英国11个产科单位开展,每家单位每年负责3000-9000例分娩。

诊断标准与关键阈值

  • 疑似子痫前期定义:新发或原有高血压加重、试纸蛋白尿、上腹痛或右上腹疼痛、头痛伴视觉障碍、胎儿生长受限,或提示疾病的异常母体血液检查(如血小板减少或肝肾功能异常)。

处置流程与药物剂量

  • 干预组:公开循环PlGF检测结果,并联合临床管理算法进行管理。
  • 对照组:常规护理,同时进行PlGF检测但结果对临床医生和孕妇 conceal。
  • 各产科单位随机分配至区块,区块代表干预启动时间,在整个试验期间以等间隔6周依次启动;启动时该单位开始使用干预。

研究设计与关键结果

  • 研究类型:多中心、实用性、阶梯楔形整群随机对照试验,纳入英国11个产科单位,2016年6月13日至2017年10月27日筛查1035例疑似子痫前期孕妇,12例(1%)不符合纳入标准,1023例合格孕妇中干预组576例(56%)、对照组447例(44%)。
  • 干预组3例(1%)失访,573例(99%)纳入分析;对照组1例(<1%)撤回随访数据收集同意,446例(>99%)纳入分析。
  • 主要终点:子痫前期确诊中位时间公开检测组1.9天 vs conceal检测组4.1天(时间比0.36,95%CI 0.15-0.87;p=0.027)。
  • 母体严重不良结局:干预组22/573例(4%) vs 对照组24/447例(5%)(校正OR 0.32,95%CI 0.11-0.96;p=0.043)。
  • 围产儿不良结局:干预组14% vs 对照组15%(OR 1.45,95%CI 0.73-2.90),无差异证据。
  • 分娩孕周:干预组36.8周 vs 对照组36.6周(均差-0.52,95%CI -0.63至0.73)。

证据类型、等级与局限

  • 证据类型:多中心、实用性、阶梯楔形整群随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在疑似子痫前期孕妇中,公开PlGF检测结果并联合临床管理算法,可缩短临床确诊子痫前期的时间。
  • 作者认为,在实施PlGF检测的单位,母体不良结局发生率较低,与临床管理算法推荐采用目标性加强监测一致。
  • 作者认为,疑似子痫前期孕妇采用PlGF检测得到本研究结果支持。

指南或共识出处

  • 研究注册号ISRCTN 16842031;资助方National Institute for Health Research。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Previous prospective cohort studies have shown that angiogenic factors have a high diagnostic accuracy in women with suspected pre-eclampsia, but we remain uncertain of the effectiveness of these tests in a real-world setting. We therefore aimed to determine whether knowledge of the circulating concentration of placental growth factor (PlGF), an angiogenic factor, integrated with a clinical management algorithm, decreased the time for clinicians to make a diagnosis in women with suspected pre-eclampsia, and whether this approach reduced subsequent maternal or perinatal adverse outcomes.

METHODS: We did a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial in 11 maternity units in the UK, which were each responsible for 3000-9000 deliveries per year. Women aged 18 years and older who presented with suspected pre-eclampsia between 20 weeks and 0 days of gestation and 36 weeks and 6 days of gestation, with a live, singleton fetus were invited to participate by the clinical research team. Suspected pre-eclampsia was defined as new-onset or worsening of existing hypertension, dipstick proteinuria, epigastric or right upper-quadrant pain, headache with visual disturbances, fetal growth restriction, or abnormal maternal blood tests that were suggestive of disease (such as thrombocytopenia or hepatic or renal dysfunction). Women were approached individually, they consented for study inclusion, and they were asked to give blood samples. We randomly allocated the maternity units, representing the clusters, to blocks. Blocks represented an intervention initiation time, which occurred at equally spaced 6-week intervals throughout the trial. At the start of the trial, all units had usual care (in which PlGF measurements were also taken but were concealed from clinicians and women). At the initiation time of each successive block, a site began to use the intervention (in which the circulating PlGF measurement was revealed and a clinical management algorithm was used). Enrolment of women continued for the duration of the blocks either to concealed PlGF testing, or after implementation, to revealed PlGF testing. The primary outcome was the time from presentation with suspected pre-eclampsia to documented pre-eclampsia in women enrolled in the trial who received a diagnosis of pre-eclampsia by their treating clinicians. This trial is registered with ISRCTN, number 16842031.

FINDINGS: Between June 13, 2016, and Oct 27, 2017, we enrolled and assessed 1035 women with suspected pre-eclampsia. 12 (1%) women were found to be ineligible. Of the 1023 eligible women, 576 (56%) women were assigned to the intervention (revealed testing) group, and 447 (44%) women were assigned to receive usual care with additional concealed testing (concealed testing group). Three (1%) women in the revealed testing group were lost to follow-up, so 573 (99%) women in this group were included in the analyses. One (<1%) woman in the concealed testing group withdrew consent to follow-up data collection, so 446 (>99%) women in this group were included in the analyses. The median time to pre-eclampsia diagnosis was 4·1 days with concealed testing versus 1·9 days with revealed testing (time ratio 0·36, 95% CI 0·15-0·87; p=0·027). Maternal severe adverse outcomes were reported in 24 (5%) of 447 women in the concealed testing group versus 22 (4%) of 573 women in the revealed testing group (adjusted odds ratio 0·32, 95% CI 0·11-0·96; p=0·043), but there was no evidence of a difference in perinatal adverse outcomes (15% vs 14%, 1·45, 0·73-2·90) or gestation at delivery (36·6 weeks vs 36·8 weeks; mean difference -0·52, 95% CI -0·63 to 0·73).

INTERPRETATION: We found that the availability of PlGF test results substantially reduced the time to clinical confirmation of pre-eclampsia. Where PlGF was implemented, we found a lower incidence of maternal adverse outcomes, consistent with adoption of targeted, enhanced surveillance, as recommended in the clinical management algorithm for clinicians. Adoption of PlGF testing in women with suspected pre-eclampsia is supported by the results of this study.

FUNDING: National Institute for Health Research.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Duhig KE, Myers J, Seed PT, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019. PMID: 30948284. doi:10.1016/S0140-6736(18)33212-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。